What Is BPC-157? Uses, Risks, and FDA Status
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic peptide made up of 15 amino acids, derived from a protein naturally found in human gastric juice. It has been studied since the early 1990s, primarily in animal models, for its potential to accelerate tissue repair and reduce inflammation. It is one of the most widely discussed peptides in regenerative medicine and biohacking communities.
How Does BPC-157 Work?
BPC-157 appears to promote healing by stimulating the growth of new blood vessels (angiogenesis) and upregulating growth factors like VEGF and EGF that are involved in tissue repair. It also modulates the nitric oxide system, which plays a role in blood flow and inflammation. In animal studies, these mechanisms translate to faster healing of tendons, ligaments, muscles, gut lining, and bone. Research suggests it activates the FAK-paxillin pathway, which helps cells migrate to injury sites (Chang et al., J Pharmacol Sci, 2011).
What Is BPC-157 Used For?
Based on published preclinical research, BPC-157 has been investigated for:
- Tendon and ligament repair — Accelerated healing of Achilles tendon and MCL injuries in rat models (Staresinic et al., J Orthop Res, 2003)
- Gut healing — Protective effects against NSAID-induced gastric damage and inflammatory bowel conditions
- Muscle recovery — Faster recovery from crush injuries and muscle tears in animal studies
- Bone fracture healing — Preliminary evidence of accelerated bone repair
- Neuroprotection — Early-stage research suggesting protective effects against certain neurotoxins
What Are the Risks?
- Limited human data. The vast majority of BPC-157 research has been conducted in animal models. Published human clinical trials are scarce.
- Unknown long-term safety. No long-term human safety studies have been completed.
- Potential drug interactions. BPC-157 may interact with medications that affect blood pressure or the nitric oxide pathway.
- Injection site reactions. Redness, swelling, and discomfort at the injection site are commonly reported by users.
- Quality variability. Products sourced outside of licensed pharmacies may have inconsistent purity and dosing.
FDA Status
As of February 2026, BPC-157 has been reclassified from Category 2 to Category 1 by the FDA. This means licensed compounding pharmacies can legally prepare it with a physician prescription. BPC-157 is not FDA-approved as a drug — it is accessible through the compounding pathway. It is also scheduled for PCAC review on July 23, 2026 for potential addition to the 503A bulks list.
Key Takeaway
BPC-157 is a well-studied peptide in animal models with promising tissue-repair properties, now legally accessible through licensed compounding pharmacies under physician supervision.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.